RxDoctor Payments Data

Walid Elkhalili, MD

Internal Medicine · Fair Lawn, NJNPI 1205186756

Payments from drug & device makers

$16,594in general payments, 2019–2025

Across 571 payments — averaging $29.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Merz North America, Inc.$1K
  • Novo Nordisk$1K
  • AstraZeneca$712
  • Medtronic$688
  • GSK$459
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$16,567100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)158$7,064
Merz North America, Inc.11$1,356
Novo Nordisk63$1,076
AstraZeneca37$712
Medtronic19$688
GSK24$459
Pfizer33$419
Ironwood Pharmaceuticals, Inc4$376
Johnson & Johnson(2 entities)9$366
Amgen(2 entities)18$283
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$266
Abbott14$240
Biohaven Pharmaceutical Holding Company Ltd.11$239
Lilly USA, LLC14$216
Exact Sciences8$175
Amarin Pharma, Inc.4$166
Boehringer Ingelheim9$154
Madrigal Pharmaceuticals1$150
Kowa Pharmaceuticals America, Inc.9$146
Ferring Pharmaceuticals Inc.9$145
Sanofi-aventis U.S. LLC2$139
Abiomed2$131
Astellas Pharma US Inc7$129
Sanofi1$123
Gilead6$101
Novartis6$100
Antares Pharma, Inc.6$91
Phathom Pharmaceuticals, Inc.5$78
Corium, LLC2$66
Tolmar, Inc.4$62
Xeris Pharmaceuticals, Inc.4$62
Merck4$56
Mannkind Corporation4$55
Axsome Therapeutics, Inc.3$48
Esperion Therapeutics, Inc.3$45
Acerus Pharmaceuticals Corporation3$43
Aerin Medical Inc.1$41
Biohaven Pharmaceuticals, Inc.2$35
Shield Therapeutics Inc2$34
Teva Pharmaceuticals USA, Inc.2$31
Avanir Pharmaceuticals, Inc.2$31
Verity Pharmaceuticals Inc.2$30
Almatica Pharma LLC2$27
Otsuka America Pharmaceutical, Inc.2$27
Clarus Therapeutics Inc.2$27
Impel Pharmaceuticals Inc.1$24
Dexcom, Inc.1$20
Insulet Corporation1$19
Lundbeck LLC1$19
Vanda Pharmaceuticals Inc.1$19
Corcept Therapeutics1$18
Sun Pharmaceutical Industries Inc.1$17
Idorsia Pharmaceuticals US Inc1$17
Hikma Pharmaceuticals USA1$16
Regeneron Healthcare Solutions, Inc.1$16
VBI Vaccine (delaware) Inc.1$16
Orthogenrx Inc.1$15
Eisai Inc.1$15
Bausch Health US, LLC1$14
Incyte Corporation1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,594 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$200,738
Medicare patients
543
Services billed
4,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide89$109,370
OzempicSemaglutide91$92,846
JardianceEmpagliflozin83$85,044
FarxigaDapagliflozin Propanediol43$55,486
EliquisApixaban60$54,678
LinzessLinaclotide50$38,467
Diclofenac Sodium56$27,668
JanuviaSitagliptin Phosphate23$22,939
VascepaIcosapent Ethyl39$22,664
JanumetSitagliptin Phos/Metformin Hcl14$18,261
FiaspInsulin Aspart (Niacinamide)15$17,079
BrilintaTicagrelor16$11,140
Rosuvastatin Calcium508$9,911
EntrestoSacubitril/Valsartan12$9,518
MyrbetriqMirabegron15$8,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp$1,076$109,926106 claims
Lilly USA, LLCMounjaro$216$109,37089 claims
Boehringer IngelheimJardiance$154$85,04483 claims
AstraZenecaFarxiga, Brilinta$712$66,62659 claims
PfizerEliquis$419$54,67860 claims
MerckJanuvia, Janumet$56$41,20037 claims
AbbVieLinzess$7,064$38,46750 claims
GSKIncruse Ellipta, Breo Ellipta$459$11,94131 claims
NovartisEntresto$100$9,51812 claims
Astellas Pharma US IncMyrbetriq$129$8,45115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Fair Lawn

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →